SCHEMBL17836985

SCHEMBL17836985

CCOC(=O)c1ccc(Br)cc1-c1cccc2ccccc12

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDC25B P30305 3/20 0.54
CDC25A P30304 1/20 0.51
CDC25C P30307 1/20 0.51
ALDH1A1 P00352 3/20 0.49
SMN1; SMN2 Q16637 2/20 0.49
FNTA P49354 1/20 0.47
FNTB P49356 1/20 0.47
KDM4E B2RXH2 3/20 0.47
GLA P06280 1/20 0.47
GAA P10253 1/20 0.47
LMNA P02545 2/20 0.47
RAB9A P51151 2/20 0.47
NFKB1 P19838 1/20 0.47
NFKB2 Q00653 1/20 0.47
RELA Q04206 1/20 0.47
TSHR P16473 1/20 0.46
GABRA1 P14867 1/20 0.45
GABRB1 P18505 1/20 0.45
GABRA3 P34903 1/20 0.45
GABRB2 P47870 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17852148 0.87 ALDH1A1 (0.49) CDC25BCDC25ACDC25CALDH1A1SMN1; SMN2
SCHEMBL291900 0.86 CDC25B (0.62) CDC25BCDC25ACDC25CALDH1A1FNTA
SCHEMBL18302008 0.85 SLC6A3 (0.54) ALDH1A1SMN1; SMN2KDM4EGAATSHR
SCHEMBL4072424 0.85 CDC25B (0.68) CDC25BCDC25ACDC25CALDH1A1FNTA
SCHEMBL8158480 0.85 CA12 (0.57) ALDH1A1SMN1; SMN2LMNARAB9ATSHR
SCHEMBL18428555 0.84 CDC25B (0.67) CDC25BCDC25ACDC25CALDH1A1FNTA
SCHEMBL2129231 0.81 CDC25B (0.62) CDC25BCDC25ACDC25CALDH1A1FNTA
SCHEMBL28004714 0.80 CDC25B (0.61) CDC25BCDC25ACDC25CALDH1A1FNTA
SCHEMBL12256746 0.80 ALDH1A1 (0.58) CDC25BCDC25ACDC25CALDH1A1SMN1; SMN2
SCHEMBL17852149 0.80 SLC6A2 (0.52) CDC25BALDH1A1SMN1; SMN2KDM4EGLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160181542-A1 ANTHRACENE DERIVATIVE AND ORGANIC ELECTROLUMINESCENT ELEMENT USING SAME IDEMITSU KOSAN CO., LTD. (JP) 2016-06-23 US disclosed
US-20160181542-A1 ANTHRACENE DERIVATIVE AND ORGANIC ELECTROLUMINESCENT ELEMENT USING SAME IDEMITSU KOSAN CO., LTD. (JP) 2016-06-23 US disclosed
US-20160181542-A1 ANTHRACENE DERIVATIVE AND ORGANIC ELECTROLUMINESCENT ELEMENT USING SAME IDEMITSU KOSAN CO., LTD. (JP) 2016-06-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160181542-A1 ANTHRACENE DERIVATIVE AND ORGANIC ELECTROLUMINESCENT ELEMENT USING SAME L1CAM, H1-10, H1-0 CDC25B 3875/4885CDC25A 3976/4885CDC25C 4487/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.